A Virtual Reality View of Genomics, Targeted Therapeutic Options, and Treatment Sequencing for the Management of Hematologic Malignancies
Feel free to pass this invitation on to your physicians, fellows, physician assistants, nurses, pharmacists, healthcare practitioners, and any other colleagues who you believe would be interested in participating in this free educational program.
Wednesday, July 22, 2020
7:00 PM – 9:00 PM ET
Please note this Virtual program is at 7:00 PM Eastern, 6:00 PM Central, 5:00 PM Mountain, and 4:00 PM Pacific.
- Virtual reality animations
- Create your own online personalized posters
Michael R. Grunwald, MD
Chief, Leukemia Division
Associate Professor, Atrium Health
Department of Hematologic Oncology and Blood Disorders
Levine Cancer Institute
Ryan Jacobs, MD
Department of Hematology, Lymphoma Division
Assistant Professor of Medicine
Levine Cancer Institute/Atrium Health
After completing the CME activity, learners should be better able to:
- Explain how common mutations and abnormalities in patients with previously untreated and R/R CLL and AML affect treatment decision making
- Describe available and emerging therapeutic approaches for patients with previously untreated and R/R CLL and AML
- Review methods for measuring and analyzing MRD in CLL and clinical trial data providing insight into the use of MRD status in the management of CLL
- Design evidence-based therapeutic strategies for patients with previously untreated and R/R CLL and AML based on patient characteristics
- Discuss the benefits of effective communication between health care providers and patients with previously untreated and R/R CLL and AML
This activity is intended for US-based hematologists, medical oncologists, and other healthcare providers involved in the treatment of patients with either CLL or AML.
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
This CME activity was planned and produced in accordance with the ACCME Essentials.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this live activity for a maximum of 2.0 AMA Category 1 Credits TM. Physicians should claim only the credit commensurate with the extent of their participation in the live activity.
NURSING CREDIT INFORMATION
This program would be beneficial for nurses involved in the treatment and management of patients with AML and CLL.
2.0 ANCC Contact Hours
Awarded 2.0 contact hours of continuing nursing education of RNs and APNs.
CNE ACCREDITATION STATEMENT
Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME)Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During the course of this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications
Med Learning Group makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact: Med Learning Group at email@example.com
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at: http://www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at firstname.lastname@example.org
Copyright © 2020 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.